Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Solid Biosciences (SLDB), a precision genetic medicines developer focusing on neuromuscular and cardiac diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Bo Cumbo, President and CEO, will deliver a presentation on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET).
The presentation will be accessible through a live webcast on the Company's website's Investors section under the Events page. A replay of the webcast will remain available for 30 days following the event. Institutional investors seeking meetings with management during the conference are advised to contact their J.P. Morgan representatives.
Solid Biosciences (SLDB), sviluppatore di medicinali genetici di precisione focalizzato sulle malattie neuromuscolari e cardiache, ha annunciato la sua partecipazione al 43掳 Meeting Annuale della Sanit脿 J.P. Morgan. Bo Cumbo, Presidente e CEO, presenter脿 mercoled矛 15 gennaio 2025, alle 15:45 PT (18:45 ET).
La presentazione sar脿 accessibile tramite una trasmissione in diretta sul sito web della Societ脿 nella sezione Investitori, sotto la pagina Eventi. Una registrazione della trasmissione rimarr脿 disponibile per 30 giorni dopo l'evento. Gli investitori istituzionali che desiderano incontrare la direzione durante la conferenza sono invitati a contattare i loro rappresentanti J.P. Morgan.
Solid Biosciences (SLDB), un desarrollador de medicamentos gen茅ticos de precisi贸n enfocado en enfermedades neuromusculares y card铆acas, ha anunciado su participaci贸n en la 43陋 Conferencia Anual de Atenci贸n M茅dica J.P. Morgan. Bo Cumbo, Presidente y CEO, har谩 una presentaci贸n el mi茅rcoles 15 de enero de 2025, a las 3:45 p.m. PT (6:45 p.m. ET).
La presentaci贸n ser谩 accesible a trav茅s de una transmisi贸n en vivo en la secci贸n de Inversores del sitio web de la compa帽铆a en la p谩gina de Eventos. Se mantendr谩 una repetici贸n de la transmisi贸n durante 30 d铆as despu茅s del evento. Se aconseja a los inversores institucionales que deseen reuniones con la direcci贸n durante la conferencia que se comuniquen con sus representantes de J.P. Morgan.
靻旊Μ霌� 氚旍澊鞓れ偓鞚挫柛鞀�(SLDB), 鞁犼步攴检湣 氚� 鞁灔 歆堩櫂鞐� 齑堨爯鞚� 毵烄稑 鞝曤皜 鞙犾爠鞛� 鞚橃暯頀� 臧滊皽鞐呾泊臧� 鞝�43須� JP氇贝 項姢旒�鞏� 旎嵓霟办姢 彀胳棳毳� 氚滍憸頄堨姷雼堧嫟. 氤� 旎措炒 颁贰翱电� 2025雲� 1鞗� 15鞚� 靾橃殧鞚� 鞓ろ泟 3鞁� 45攵� PT (鞓ろ泟 6鞁� 45攵� ET)鞐� 氚滍憸毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
氚滍憸電� 須岇偓 鞗轨偓鞚错姼鞚� 韴瀽鞛� 靹轨厴 鞚措菠韸� 韼橃澊歆�毳� 韱淀暣 霛检澊敫� 鞗轨簮鞀ろ姼搿� 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟. 頄夓偓臧� 雭濍倻 頉� 30鞚� 霃欖晥 雼れ嫓氤搓赴 靹滊箘鞀るゼ 鞝滉车頃� 鞓堨爼鞛呺媹雼�. 旎嵓霟办姢 旮瓣皠 霃欖晥 瓴届榿歆勱臣鞚� 氙疙寘鞚� 鞗愴晿電� 旮瓣磤 韴瀽鞛愲摛鞚� JP氇贝 雽�響滌棎瓴� 氍胳潣頃橃嫓旮� 氚旊瀺雼堧嫟.
Solid Biosciences (SLDB), un d茅veloppeur de m茅dicaments g茅n茅tiques de pr茅cision ax茅 sur les maladies neuromusculaires et cardiaques, a annonc茅 sa participation 脿 la 43e Conf茅rence Annuelle de la Sant茅 J.P. Morgan. Bo Cumbo, pr茅sident et PDG, fera une pr茅sentation le mercredi 15 janvier 2025, 脿 15h45 PT (18h45 ET).
La pr茅sentation sera accessible via un webinaire en direct dans la section Investisseurs du site web de l'entreprise, sous la page 脡v茅nements. Une r茅p茅tition du webinaire sera disponible pendant 30 jours apr猫s l'茅v茅nement. Les investisseurs institutionnels souhaitant des r茅unions avec la direction pendant la conf茅rence sont invit茅s 脿 contacter leurs repr茅sentants J.P. Morgan.
Solid Biosciences (SLDB), ein Entwickler pr盲ziser gentherapeutischer Mittel mit Schwerpunkt auf neuromuskul盲ren und Herzerkrankungen, hat seine Teilnahme an der 43. Jahrestagung der J.P. Morgan Healthcare Conference bekanntgegeben. Bo Cumbo, Pr盲sident und CEO, wird am Mittwoch, den 15. Januar 2025, um 15:45 Uhr PT (18:45 Uhr ET) eine Pr盲sentation halten.
Die Pr盲sentation wird 眉ber einen Live-Stream im Investorenbereich der Unternehmenswebsite unter der Veranstaltungsseite zug盲nglich sein. Eine Aufzeichnung des Webcasts wird 30 Tage nach der Veranstaltung verf眉gbar bleiben. Institutionelle Investoren, die w盲hrend der Konferenz Meetings mit dem Management suchen, werden gebeten, ihre J.P. Morgan Ansprechpartner zu kontaktieren.
- None.
- None.
CHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the 鈥淐ompany鈥� or 鈥淪olid鈥�), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET).
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by聽. A webcast replay will be archived for 30 days on the Events page.
Institutional investors interested in meeting with management during the conference may reach out to their J.P. Morgan representatives.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-212 for the treatment of Friedreich鈥檚 ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid鈥檚 mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit .
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
Media Contact:
Glenn Silver
FINN Partners
FAQ
When is Solid Biosciences (SLDB) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Solid Biosciences' (SLDB) J.P. Morgan Healthcare Conference presentation?
How long will the replay of SLDB's J.P. Morgan Healthcare Conference presentation be available?
What therapeutic areas does Solid Biosciences (SLDB) focus on?
How can institutional investors arrange meetings with SLDB management during the conference?
